This company listing is no longer active
This company may still be operating, however this listing is no longer active. Find out why through their latest events.
Zymergen（ZY）株式概要
Zymergen Inc. design, develop, and commercialize microbes, molecules, and materials. 詳細
ZY Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Zymergen Inc. 競合他社
価格と性能
| 過去の株価 | |
|---|---|
| 現在の株価 | US$2.43 |
| 52週高値 | US$11.87 |
| 52週安値 | US$1.10 |
| ベータ | 0 |
| 1ヶ月の変化 | -6.90% |
| 3ヶ月変化 | 21.50% |
| 1年変化 | -76.75% |
| 3年間の変化 | n/a |
| 5年間の変化 | n/a |
| IPOからの変化 | -93.55% |
最新ニュース
Seeking Alpha • Aug 25
Zymergen chief scientific officer to depart as company lays off more employees
Zach Serber, chief scientific officer of Zymergen (NASDAQ:ZY) and a co-founder, is leaving the company on Sept. 22. Zymergen (ZY) also said it is laying off another 80 employees. This follows the termination of 80 employees in late July. The company's shares are down 63% year to date. Seeking Alpha's Quant Rating views Zymergen (ZY) as a hold.Seeking Alpha • Jul 26
Zymergen: Ginkgo Bioworks Acquisition
An acquisition was probably the only viable option for Zymergen, but shareholders are likely to be disappointed by the price, given the company’s ambitions at the IPO. The deal makes sense for Ginkgo as it reduces competition and expands its capabilities at a minimal cost. An all-stock transaction gives Zymergen shareholders exposure to a company with much brighter prospects, but there is a significant downside risk if Ginkgo stumbles in the future. Ginkgo Bioworks (DNA) has entered into an agreement to acquire Zymergen (ZY). While Zymergen shareholders are unlikely to be thrilled by the price, the company's financial position gave them little option. Ginkgo continues to solidify their position as the leading synbio platform, but is richly valued based on current operating metrics. The all-stock deal gives Zymergen shareholders exposure to a company with better prospects, but also introduces valuation risk. Zymergen At the time of Zymergen's IPO, the company appeared to be reaching an inflection point, with multiple products nearing commercialization. Zymergen's narrative and valuation fell apart soon after though, when the company announced these products were not viable and that the CEO would be stepping down. Since then, Zymergen has been in a race to restructure costs and create revenue streams, in the hope of staving off bankruptcy. Given the company's cost structure, balance sheet and the state of equity markets, an acquisition was probably the best hope for shareholders. Figure 1: Zymergen Target Opportunities (source: Zymergen) Automation & Tech Platform Zymergen had been in the process of offering modular automation systems to the market, to commercialize their lab expertise. In particular, Octant had purchased 11 of Zymergen's Reconfigurable Automation Carts (RACs) to help scale their drug discovery platform. These RACs are designed to improve the throughput, efficiency, and reliability of lab operations and are controlled by Zymergen's cloud software. Zymergen previously stated that they had approximately 30 prospects, with a typical 10-RAC system costing between 1-2.5 million USD and requiring approximately 400,000 USD in annual software and support costs. Figure 2: Zymergen RAC (source: Zymergen) Advanced Materials Zymergen have been developing materials, which they have bracketed under agriculture, water repellency, advanced polymers and enzymes. Zymergen has a fairly mature nitrogen fixation program that uses engineered microbes to replace nitrogen fertilizers. In their water repellency program, Zymergen have been exploring coated straws and recently demonstrated the successful conversion of their coated paper into an end product manufactured on a potential customer's production line. Within advanced polymers, Zymergen has announced a supply agreement with 3D4Makers to provide Polyimide for use in 3D printing. Polyimide is a high-strength polymer that is flame retardant, has excellent insulating properties and excellent thermal stability. The polymer will be offered to 3D4Maker's customers for applications like aerospace, automotive, and transportation. Zymergen has also developed mRNA enzymes (VCE and 2'-O-MT) for use in vaccines. Drug Discovery Zymergen is leveraging their metagenomic database to uncover natural molecules that inhibit targets of interest, with an initial focus on oncology. There are millions of novel bioactives from uncultured bacteria and fungi and Zymergen are computationally predicting the activity of these bioactives against human targets. Figure 3: Therapeutic Classes and Potential Targets (source: Zymergen) Ginkgo Acquisition Ginkgo is acquiring Zymergen in an all-stock transaction that values Zymergen at approximately a 300 million USD market capitalization. The stated aim of the acquisition is to accelerate the development of Ginkgo's platform. Ginkgo plan to integrate Zymergen's automation, software, data science tools and biological assets. Zymergen's core technical team will be retained, which will help Ginkgo to fulfill their hiring plans. Strategic alternatives will be considered for Zymergen's Advanced Materials and Drug Discovery businesses. It is possible that these will be spun out and become Ginkgo customers, in a similar manner to companies like Joyn Bio and Motif Food Works. Ginkgo has been active in M&A in recent years, with acquisitions either building on the capabilities of their Foundries, or providing the necessary vertical expertise to attract customers and successfully bring products to market. Figure 4: Ginkgo Acquisitions (source: Ginkgo Bioworks) Ginkgo is doing the right thing by conducting countercyclical M&A, but it is unclear how much value Zymergen will add. Ginkgo's appeal should be that they have singular capabilities, and acquiring competing synbio companies for their technology undermines this. Jason Kelly stated that approximately 70% of the deal's value lies in Zymergen's physical assets (foundry / automation). There could be significant issues integrating these assets into Ginkgo's workflows, although Zymergen's successful rollout of automation solutions at Octant has given Ginkgo confidence that this can be managed. Figure 5: Ginkgo's Plan for Zymergen's Assets (source: Ginkgo Bioworks) In its current state, Zymergen would significantly weaken Ginkgo's financial position, and hence it is likely that there will be a large reduction in headcount. Zymergen had approximately 500 employees at the end of 2021 in comparison to Ginkgo's 640 employees, but is not currently generating any meaningful revenue.Seeking Alpha • Jul 14
Zymergen expands agreement with Octant on developing breakthrough medicines
Biotech company Zymergen (NASDAQ:ZY) expanded an agreement with therapeutics company Octant in relation to developing breakthrough medicines. Octant has more than doubled its initial investment through the purchase of six additional Reconfigurable Automation Carts, or RAC, units. ZY shares were trading +2.15% post-market. Source: Press ReleaseRecent updates
株主還元
| ZY | US Chemicals | US 市場 | |
|---|---|---|---|
| 7D | 3.4% | 0.1% | 1.1% |
| 1Y | -76.7% | 8.9% | 28.7% |
業界別リターン: ZY過去 1 年間で8.9 % の収益を上げたUS Chemicals業界を下回りました。
リターン対市場: ZYは、過去 1 年間で28.7 % のリターンを上げたUS市場を下回りました。
価格変動
| ZY volatility | |
|---|---|
| ZY Average Weekly Movement | 13.3% |
| Chemicals Industry Average Movement | 7.5% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.1% |
安定した株価: ZYの株価は、 US市場と比較して過去 3 か月間で変動しています。
時間の経過による変動: ZYの weekly volatility ( 13% ) は過去 1 年間安定していますが、依然としてUSの株式の 75% よりも高くなっています。
会社概要
| 設立 | 従業員 | CEO（最高経営責任者 | ウェブサイト |
|---|---|---|---|
| 2013 | 505 | n/a | www.zymergen.com |
Zymergen Inc. 基礎のまとめ
| ZY 基礎統計学 | |
|---|---|
| 時価総額 | US$253.58m |
| 収益（TTM） | -US$364.92m |
| 売上高(TTM) | US$14.58m |
17.4x
P/Sレシオ-0.7x
PER（株価収益率ZY は割高か？
公正価値と評価分析を参照収益と収入
| ZY 損益計算書（TTM） | |
|---|---|
| 収益 | US$14.58m |
| 売上原価 | US$178.03m |
| 売上総利益 | -US$163.45m |
| その他の費用 | US$201.47m |
| 収益 | -US$364.92m |
直近の収益報告
Jun 30, 2022
次回決算日
該当なし
| 一株当たり利益（EPS） | -3.50 |
| グロス・マージン | -1,121.15% |
| 純利益率 | -2,503.04% |
| 有利子負債／自己資本比率 | 0% |
ZY の長期的なパフォーマンスは？
過去の実績と比較を見る企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2022/10/23 00:34 |
| 終値 | 2022/10/18 00:00 |
| 収益 | 2022/06/30 |
| 年間収益 | 2021/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Zymergen Inc. これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。5
| アナリスト | 機関 |
|---|---|
| Derik de Bruin | BofA Global Research |
| Matthew Sykes | Goldman Sachs |
| Sriharsha Pappu | HSBC |